Michael Dickinson is the Lead of the Aggressive Lymphoma stream within the Integrated Haematology Service, a team of 16 haematologists and specialist radiation oncologists. He is experienced as a principal investigator in phase I/II clinical trials of new anticancer drugs across a breadth of haematological malignancies. His investigator-initiated studies have focused on the role of epigenetic modifiers in haematological malignancies and of eltrombopag as a supportive care agent in myeloid malignancy. Michael's clinical research includes industry and investigator-led trials in aggressive lymphomas, MDS/AML and phase 1 studies.
Michael prides himself on providing thorough and personal care to his patients throughout their cancer journey.
Current focus is:
1. Continuous improvement of the lymphoma assessment service for patients with a new diagnosis of lymphoma or a lump for investigation; delivering best in the country diagnosis and staging evaluation in collaboration with Australia's leading haematopathology and molecular pathology centre, and with PET-centre physicians with a special interest in lymphoma.
2. Providing the best options for patients where standard treatments fail: Australia's largest and most comprehensive trials programme for patients with relapsed or treatment -refractory lymphoma. Our early phase trial pipeline allows patients the best opportunity to harness new targeted treatments for cell signalling in lymphoma, and immunotherapies. At Peter Mac, our special expertise is in the development of the BCL-2 inhibitors (eg venetoclax), epigenetic therapies, and CART.
3. Providing new treatment options for patients with T-cell lymphoma.
4. Building our CART programme, both as a standard of care (if public funding is approved) and also providing CART trial options for patients with lymphoma.
5. Providing a training environment for tomorrow's experts.
2013: Julie Borschmann Research Fellow, University of Melbourne
2018: Peter MacCallum Cancer Centre Clinical Research Fellowship